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That body weight is regulated has
been evident to physiologists for
many years. When access to food is
restricted, animals increase their
desire for food and indulge heartily
when food reappears. To conserve
energy during caloric restriction,
appetite is regulated and the overall
metabolic rate declines. Conversely,
to resist obesity, forced overfeeding
suppresses appetite and increases
metabolic rate. As tiny surgical or
chemical lesions within the
hypothalamus in the brain can
produce obesity or leanness by
disrupting the link between appetite
and metabolic rate, it had been
surmised that the hypothalamus has a
key integrative role in energy balance,
as it does in many other homeostatic
processes. Physiological control of
energy balance, although reasonably
effective, is obviously imperfect, as
judged by the prevalence of obesity
in the modern world.
Molecular factors
Until recently, none of the molecular
elements of energy homeostasis had
been identified. But as several
genetic syndromes featuring severe
obesity have been identified in mice,
and these syndromes are typically
characterized by both increased
appetite and decreased energy
expenditure, a genetic approach
should eventually identify critical
control points for energy
homeostasis. The results of the past
five years have, however, exceeded
all expectations, and the clear
outlines of a carefully balanced
regulatory system are now evident.
Energy homeostasis is governed
by three distinct but integrated
factors: appetite, energy expenditure
and linked endocrine/metabolic
pathways. The control of appetite
requires several physiological inputs
to the central nervous system (CNS),
and most critically to the
hypothalamus. These include a means
of monitoring the levels of neural and
endocrine messages from the gut
signaling recent food ingestion, the
levels of various molecules in the
blood, such as glucose, and the levels
of a previously elusive signal
reflecting the overall state of energy
stores. This signal is now known to be
leptin, the product of the ob gene.
Cultural and psychological factors
should not be ignored as important
inputs to appetite control, but these
are difficult to integrate into an
understanding of the molecular basis
of energy homeostasis.
The regulation of energy
expenditure for all the
energy-requiring processes in the
body is complex. Two particular
elements of this regulation are tightly
controlled: the first is the key role
that thyroid hormone activity has in
the regulation of metabolic rate; the
second is the system for altering the
state of ‘mitochondrial uncoupling’
— the tightness with which substrate
oxidation is linked to ATP formation.
In uncoupled mitochondria, substrate
oxidation proceeds without ATP
formation, the net result being
production of heat, rather than
storage of energy as ATP. Regulated
mitochondrial uncoupling occurs
either in brown adipose tissue, which
expresses uncoupling protein 1, or
elsewhere in the body, through the
actions of the recently identified
uncoupling proteins 2 and 3. Thyroid
hormone may regulate metabolic rate
in part by affecting expression of
uncoupling proteins. The brain
controls the thyroid axis through the
neuropeptide thyrotropin releasing
hormone (TRH), and influences
mitochondrial uncoupling through
the autonomic nervous system, which
innervates brown adipose tissue.
Long-term energy homeostasis
requires that energy needs are linked
to the disposition  of metabolic fuels
— which is orchestrated mainly by
insulin — and to neuroendocrine
function, including the control of
reproduction, which is actively
suppressed during periods of
energy deficit.
Maintaining homeostasis
So how do these disparate systems
work in concert to maintain
homeostasis? A fundamental
component of the regulatory system
is the hormone leptin. This 16 kDa
peptide is a member of the cytokine
gene family and is expressed
predominantly in adipose cells. Its
expression rises as energy stores
increase and falls rapidly during
periods of starvation. An absence of
leptin results in severe obesity that
begins shortly after birth in both
rodents and humans; postnatal leptin
replacement reverses the disorder.
Leptin deficiency also results in
numerous other defects in endocrine
function and in insulin insensitivity.
The leptin receptor is a member
of the class I cytokine receptor
family and, in common with these
receptors, signals through the
JAK/STAT pathway. JAK is a
non-transmembrane tyrosine kinase
that associates with the leptin
receptor and is activated after the
receptor binds ligand. JAK then
phosphorylates STAT transcription
factors, which dimerize and move to
the nucleus where they regulate
gene transcription. A mutation
affecting the structure of the leptin
receptor causes obesity that is
refractory to leptin therapy. Taken
together, these properties suggest
that leptin controls an important
metabolic switch.
Control in the brain
Leptin acts primarily within the
brain, and particularly in the
hypothalamus. The end result of
normal leptin activity can, in many
cases, be mimicked by the
administration of tiny quantities of
leptin directly within the CNS, at
levels that cannot be detected in the
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peripheral circulation. Although
present in several locations inside
and outside the CNS, the signaling
form of the leptin receptor is
expressed abundantly in several
discrete cell groups within the
hypothalamus that have previously
been associated with regulation of
energy homeostasis. These include
the arcuate nucleus, the
ventromedial nucleus and the
dorsomedial nucleus. Leptin
administered into the bloodstream
affects the function of these neurons.
It has long been known that
many neuropeptides, including those
expressed within the hypothalamus,
influence food intake and/or energy
expenditure after being injected into
the brain. An important member of
this family of molecules is
neuropeptide Y (NPY), which is
widely expressed in the CNS,
including the arcuate nucleus of the
hypothalamus. NPY potently induces
rodents to eat, suppresses energy
expenditure through its effects on
the autonomic nervous system, and
can cause obesity with prolonged
administration. Expression of NPY in
the arcuate nucleus rises during
starvation, as expected for a molecule
that promotes feeding, and this
increase is related in part to the
relaxation of the inhibitory effect of
leptin on the NPY neurons when
leptin levels fall during starvation.
Although leptin-deficient mice
crossbred with NPY knockouts are
somewhat less obese, their obesity is
still severe, and mice lacking NPY
have no obvious phenotype related
to energy homeostasis. Thus, there
must be other critical leptin targets,
in addition to the NPY neurons.
Tissue-specific processing of the
proopiomelanocortin (POMC)
molecule — which gives rise to
peptide hormones including
adrenocorticotrophic hormone,
β-endorphin and α-melanocyte
stimulating hormone (α-MSH) —
has only recently been viewed as
being involved in energy balance.
There are five melanocortin
receptors, all of which are members
of the G-protein coupled receptor
family. Knockout of the
melanocortin 4 receptor (MC4R;
expressed primarily in the CNS and
especially in the hypothalamus) by
means of mutations in mice and in
humans, results in obesity. The
obesity is less severe than that
produced by leptin deficiency or
resistance, and some of the
endocrine features are absent,
suggesting that this pathway
mediates an important part, but not
all, of the leptin signalling process.
Two antagonistic ligands, each of
which is directly regulated by leptin
within the arcuate nucleus of the
hypothalamus, converge on the
MC4R receptor (see Figure 1). The
agonist is α-MSH, produced in the
POMC neurons in the arcuate
nucleus, which in turn are positively
regulated by leptin. Synthetic
antagonists of MC4R block many of
the appetite-suppressing effects of
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Figure 1
Leptin is produced and secreted by
adipocytes in the periphery. It acts
predominantly within the brain, after transport
across the blood–brain barrier. Several
groups of neurons within the arcuate nucleus
of the hypothalamus respond directly to leptin.
One group of neurons expresses POMC and
CART mRNAs, which are activated by leptin
such that expression of the neuropeptides
α-MSH and CART is increased. These
peptides inhibit food intake. Another distinct
set of neurons expresses AgRP and NPY,
which stimulate food intake. Leptin inhibits
these neurons and reduces AgRP and NPY
expression. AgRP and α-MSH act through
the MRC4 receptor; α-MSH is an agonist
and AgRP is an antagonist (broken arrow) at
this receptor. Mutation of the MRC4 receptor
causes obesity. MCH and TRH neurons are
among those that may respond to this
leptin-regulated melanocortin signal.
Ultimately, these and other neural outputs
influence hunger, the activity of the
autonomic nervous system, insulin action and
numerous endocrine systems. Many details
of the connection to these final outputs
remain unknown.
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leptin. Deletion of the POMC gene
not only causes obesity in mice and
humans but also results in
disturbances because of the loss of
other POMC peptides. The natural
MC4R antagonist is agouti-related
peptide (AgRP). Its expression in
distinct arcuate neurons is potently
inhibited by leptin. Administration
of AgRP to the brain promotes food
intake, and transgenic expression of
this peptide promotes obesity.
Thus, as leptin levels rise in the
transition from the starved to the
fed state, leptin acts in the
hypothalamus to induce expression
of α-MSH, the inhibitor of food
intake, and inhibit expression of
AgRP, the stimulator of food intake,
both of which act through a common
receptor (see Figure 1).
Other important central pathways
and mediators affect energy
homeostasis. Among these is the
cocaine and amphetamine related
transcript (CART), which is
coexpressed with POMC in arcuate
neurons and also inhibits food intake.
Melanin concentrating hormone
(MCH) is expressed in the lateral
hypothalamus, a region that in the
1940s was dubbed the ‘feeding
center’ because lesions in this region
resulted in loss of appetite. MCH
was first identified as a potential
mediator of appetite when its
mRNA was found to be present at
increased levels in hypothalami of
genetically obese mice, and to
induce feeding after injection into
the brain. Mice lacking the MCH
gene are lean and hypophagic (they
eat less). There is some evidence
that the MCH neurons have a
physical connection to NPY/AgRP
and POMC/CART neurons in the
arcuate nucleus, a finding that
begins to enable a sketch to be made
of the architecture of the
hypothalamic pathways underlying
leptin action (see Figure 1).
What is hunger?
Although recent progress in
understanding the regulation of
energy homeostasis has been
extraordinary, the metabolic
pathways have yet to be fully
identified. The identity of the
initial hypothalamic circuit for
leptin regulation of appetite does
not yet provide us with a full
understanding of what hunger really
represents to a mouse or a human
being. We don’t know how a
hypothalamic neural circuit can
change our conscious awareness of a
desire to eat, nor how this pathway
could relate to our habits and our
neuroses. Nor do we know how
olfaction and visual cues tie in to
these pathways to influence hunger,
as we all know that they do.
How diverse are the pathways
involving leptin activity on appetite,
compared with its effects on energy
expenditure and endocrine function?
Are there distinct subcircuits for
each type of activity? Initial
evidence suggests that this may be
so but the story is vague at present.
Are there other important hormonal
pathways that act in concert with
leptin? Glucocorticoids and sex
steroids modify body weight and
affect leptin levels, but a detailed
understanding of how these signals
are integrated awaits further work.
Insulin is another interesting
participant in energy homeostasis.
Some evidence supports the idea
that insulin, in addition to its classic
metabolic role, affects the
hypothalamus, although less
potently than leptin. Perhaps insulin
has a role as a positive regulator of
leptin expression (see Figure 1).
The final conundrum relates to
leptin resistance, which seems to
underlie the proclivity of humans
and many strains of mice to become
obese when food supplies are
abundant and the need to expend
energy is limited. In these
situations, leptin concentrations rise
to a level that should result in
leanness but, paradoxically, this is
not the outcome and we do not
know why. Current work on leptin
resistance is concentrating on the
possibility that the access of leptin
to its sites of action in the CNS is
blocked somehow, and/or that there
are defects in leptin signal
transduction in responsive neurons.
Whatever the mechanism, leptin
resistance seems to reflect an
evolutionary imperative to allow
energy storage to take place at times
of abundance. Hence, leptin should
be viewed as a switch between the
fed and the starved states, and not
as a regulator of obesity.
The discovery of leptin and some
of its biochemical and cellular
targets in the hypothalamus
establish a new context for
considering the regulation of energy
homeostasis and body weight. The
really big questions that remain
unanswered involve the
identification of the neural circuits
through which the leptin signal is
integrated with other critical
information relevant to homeostasis,
and the details of the efferent
pathways through which the brain
controls both metabolism in the
peripheral tissues and the awareness
of hunger within the brain. These
questions are certain to be
vigorously explored over the next
several years.
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